Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 09 2021
03 09 2021
Historique:
received:
23
03
2021
accepted:
10
08
2021
entrez:
4
9
2021
pubmed:
5
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Ascorbic acid represents an appealing option for clinicians to utilize in the context of the global COVID-19 pandemic due to its proposed clinical efficacy, relative safety, and low cost. The aim of this study was to evaluate the efficacy and safety of using ascorbic acid in supplemental doses as adjunctive therapy for patients critically ill with COVID-19. This was a two-center, non-interventional, retrospective cohort study. All critically ill adult patients admitted to ICU with a confirmed COVID-19 diagnosis between March 1st and December 31st, 2020, were included in the final analysis. The study was conducted at two large governmental tertiary hospitals in Saudi Arabia. The purpose was to investigate the clinical outcomes of low-dose ascorbic acid as adjunctive therapy in COVID-19 after propensity score matching using baseline severity scores, systematic use of corticosteroids, and study centers. A number of 739 patients were included in this study, among whom 296 patients were included after propensity score matching. There was no association between the administration of ascorbic acid and in-hospital mortality or the 30-day mortality [OR (95% CI) 0.77 (0.47, 1.23), p value = 0.27 and OR (95% CI) 0.73 (0.43, 1.20), p value = 0.21, respectively]. Using ascorbic acid was associated with a lower incidence of thrombosis compared with the non-ascorbic-acid group [6.1% vs. 13% respectively; OR (95% CI) 0.42 (0.184, 0.937), p value = 0.03]. Low dose of ascorbic acid as an adjunctive therapy in COVID-19 critically ill patients was not associated with mortality benefits, but it was associated with a lower incidence of thrombosis. Further studies are required to confirm these findings.
Identifiants
pubmed: 34480041
doi: 10.1038/s41598-021-96703-y
pii: 10.1038/s41598-021-96703-y
pmc: PMC8417267
doi:
Substances chimiques
Ascorbic Acid
PQ6CK8PD0R
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
17648Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Int J Vitam Nutr Res. 1994;64(3):212-9
pubmed: 7814237
Am J Clin Nutr. 1993 Feb;57(2):170-4
pubmed: 8185726
Ann Surg. 2002 Dec;236(6):814-22
pubmed: 12454520
J Crit Care. 2018 Oct;47:211-218
pubmed: 30029205
JAMA Netw Open. 2021 Feb 1;4(2):e210369
pubmed: 33576820
Adv Exp Med Biol. 1981;135:1-25
pubmed: 7010958
JAMA. 2019 Oct 1;322(13):1261-1270
pubmed: 31573637
Eur J Pharmacol. 2020 Feb 5;868:172889
pubmed: 31870831
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
JPEN J Parenter Enteral Nutr. 2019 Mar;43(3):335-346
pubmed: 30452091
World J Crit Care Med. 2012 Apr 04;1(2):40-5
pubmed: 24701400
Crit Care Med. 2011 Jun;39(6):1454-60
pubmed: 21358394
Int J Infect Dis. 2021 Apr;105:180-187
pubmed: 33601030
J Res Pharm Pract. 2016 Apr-Jun;5(2):94-100
pubmed: 27162802
Chest. 2017 Jun;151(6):1229-1238
pubmed: 27940189
Ann Intensive Care. 2021 Jan 9;11(1):5
pubmed: 33420963
Brief Bioinform. 2021 May 20;22(3):
pubmed: 32393985
Nutrients. 2017 Nov 03;9(11):
pubmed: 29099763
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Crit Care. 2017 Dec 11;21(1):300
pubmed: 29228951
Nutrients. 2019 Mar 27;11(4):
pubmed: 30934660
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
J Transl Med. 2014 Jan 31;12:32
pubmed: 24484547
JAMA. 2020 Feb 4;323(5):423-431
pubmed: 31950979
Tuberc Respir Dis (Seoul). 2020 Jul;83(3):248-254
pubmed: 32539309
J Pharm Pract. 2023 Feb;36(1):60-66
pubmed: 34098784
Crit Care Med. 1996 Mar;24(3):392-7
pubmed: 8625625
Microb Pathog. 2018 Feb;115:239-250
pubmed: 29274459